Last reviewed · How we verify
testosterone gel (Androgel)
Testosterone gel replaces deficient endogenous testosterone by transdermal absorption to restore normal androgen levels.
Testosterone gel replaces deficient endogenous testosterone by transdermal absorption to restore normal androgen levels. Used for Testosterone replacement therapy in adult males with hypogonadism.
At a glance
| Generic name | testosterone gel (Androgel) |
|---|---|
| Sponsor | Beersheva Mental Health Center |
| Drug class | Androgen replacement therapy |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Androgel is a topical testosterone replacement therapy that delivers testosterone through the skin into systemic circulation. It binds to androgen receptors throughout the body to restore physiological testosterone levels in hypogonadal men, promoting development and maintenance of male sexual characteristics, muscle mass, bone density, and other androgen-dependent functions.
Approved indications
- Testosterone replacement therapy in adult males with hypogonadism
Common side effects
- Skin irritation at application site
- Acne
- Polycythemia
- Gynecomastia
- Prostate-related events
Key clinical trials
- Body Composition Assessment in Transgender Population.
- Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (PHASE4)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (PHASE1)
- Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance (PHASE4)
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- Testosterone and Neural Function (EARLY_PHASE1)
- Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- testosterone gel (Androgel) CI brief — competitive landscape report
- testosterone gel (Androgel) updates RSS · CI watch RSS
- Beersheva Mental Health Center portfolio CI